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Abstract: 
Multiple myeloma (MM) is a progressive, malignant neoplasia with a 
worldwide, age-standardized annual incidence of 1.5 per 100,000 
individuals and 5-year prevalence around 230,000 patients. Main favorable 
prognostic factors are younger age, low-moderate cytogenetic risk, and 
undergoing stem cell transplantation. Our aim was to estimate the size of 
the patient population with MM eligible to receive a new MM therapy at 
different lines of therapy in the US.  
Methods:  
We constructed a compartmental, differential equation model representing 
the flow of MM patients from diagnosis to death, via two possible treatment 
pathways and distinguished in four groups based on prognostic factors. 
Parameters were obtained from published references, available statistics, 
and assumptions. The model was used to estimate number of diagnosed 
MM patients and number of patient transitions from one line of therapy to 
the next over one-year. Model output included 95% credible intervals (CI) 
from probabilistic sensitivity analyses.  
Results:  
The base-case estimates were 80,219 patients living with MM, including 
70,375 on treatment, 780 symptomatic untreated patients, and 9,064 
asymptomatic untreated patients. Over a one-year period, the number of 
MM patients on treatment line 1 was estimated at 23,629 (CI 22,236-
25,029), and the number of transitions from treatment line 1 to treatment 
line 2 estimated at 14,423.  
Conclusions:  
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The size of the patient population with MM on different lines of therapy and 
in-patient subgroups of interest estimated from this epidemiologic model 
can be used to assess the number of patients who could benefit from new 
MM therapies and their corresponding budgetary impact.  
  
 
 
Page 1 of 50
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
1 
 
Patient population with multiple myeloma and transitions across different lines of 
therapy in the US: an epidemiologic model 
Running Head: Multiple myeloma lines of therapy: an epidemiologic model 
 
Cid Ruzafa J1, Merinopoulou E1, Baggaley RF2, Leighton P1, Werther W3, Felici D3, Cox A1 
1
 Retrospective Observational Studies, Evidera, London, UK; 2 Department of Infectious 
Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; 3 Onyx 
Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA 
 
Keywords: Epidemiology, multiple myeloma, prevalence, model, treatment line 
Key Points: 
- The estimated number of patients with MM in the US provided by the epidemiology 
model was consistent with the figure reported by SEER. 
- The distribution of the patient population with MM on different lines of therapy and in 
patient subgroups of interest can be estimated from the epidemiologic model. 
- The size of the patient population with MM on different lines of therapy and in patient 
subgroups can be used to assess the number of patients who could benefit from new 
MM therapies, information required for budget impact analysis and to support the 
planning of healthcare services. 
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ABSTRACT 
Purpose:  
Multiple myeloma (MM) is a progressive, malignant neoplasia with a worldwide, age-
standardized annual incidence of 1.5 per 100,000 individuals and 5-year prevalence around 
230,000 patients. Main favorable prognostic factors are younger age, low-moderate 
cytogenetic risk, and undergoing stem cell transplantation. Our aim was to estimate the size 
of the patient population with MM eligible to receive a new MM therapy at different lines of 
therapy in the US.  
Methods:  
We constructed a compartmental, differential equation model representing the flow of MM 
patients from diagnosis to death, via two possible treatment pathways and distinguished in 
four groups based on prognostic factors. Parameters were obtained from published 
references, available statistics, and assumptions. The model was used to estimate number 
of diagnosed MM patients and number of patient transitions from one line of therapy to the 
next over one-year. Model output included 95% credible intervals (CI) from probabilistic 
sensitivity analyses. 
Results:  
The base-case estimates were 80,219 patients living with MM, including 70,375 on 
treatment, 780 symptomatic untreated patients, and 9,064 asymptomatic untreated patients. 
Over a one-year period, the number of MM patients on treatment line 1 was estimated at 
23,629 (CI 22,236-25,029), and the number of transitions from treatment line 1 to treatment 
line 2 estimated at 14,423. 
Conclusions:  
The size of the patient population with MM on different lines of therapy and in-patient 
subgroups of interest estimated from this epidemiologic model can be used to assess the 
number of patients who could benefit from new MM therapies and their corresponding 
budgetary impact. 
Word count: 250 
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INTRODUCTION 
Multiple myeloma (MM) is a progressive, hematologic malignancy originating from plasma 
cells and with the most negative long-term prognosis among lymphoid malignancies.1,2 MM 
accounts for approximately 1% of all cancers and 10-12% of hematologic malignancies, with 
a worldwide age-standardized annual incidence of 1.5 per 100,000 or estimates of around 
115,000 new cases per year, a rather small number compared to other cancers and chronic 
conditions.2-4 MM has an estimated worldwide 5-year prevalence of around 230,000 
patients.4 Older age is associated with unfavorable outcomes,1,5 and there are no apparent 
prognostic differences associated with gender.1 The presence of certain chromosomal 
abnormalities is also a negative prognostic factor.5-8  
MM treatment is intended to control the symptomatic disease and minimize organ damage; 
however, relapse is likely. From high-dose therapy followed by autologous stem cell 
transplantation for candidates in good condition,7,9 to allogeneic stem cell transplantation 
(SCT) in young patients with high-risk disease,7,10 and to novel agents introduced in recent 
years,2,7,11,12 all are associated with prolonged survival of patients with this incurable 
disease.5,7,9,13-15 More than 10 drugs and a greater number of drug combinations offer 
therapeutic options to patients who have relapsed or are refractory to previous treatments 
and can result in patients receiving multiple lines of therapy.5,7 The prevalence of MM is 
likely to increase as a result of ageing societies and improved survival of patients. Multiple 
lines of therapy for an increasing number of patients with MM translate into increasing 
resource requirements at subsequent lines of therapy16 and competition among MM 
treatment alternatives on pharmacoeconomic grounds.17-19 
Epidemiologic information including disease incidence, prevalence and mortality are inputs 
for burden of disease and cost-effectiveness analyses that aim to inform policy-making, 
planning and research prioritization in health care.20 Previous studies have used 
mathematical modeling techniques to project the prevalence of chronic conditions such as 
diabetes and chronic kidney disease into the near or distant future.21-23 In oncology, an 
epidemiologic model was used to estimate disease prevalence and the absolute number of 
patients at first-, second-, and third line of therapy for gastrointestinal stromal tumors,24 
providing useful information for budget impact analysis and healthcare services planning.20  
In the absence of current data on the number of patients with MM by line of therapy in the 
US, the objectives of this study were to estimate the current number of patients with MM who 
are potentially eligible to receive a new MM therapy at different lines of therapy in the US, 
and to estimate the corresponding number of patient transitions from one line of therapy to 
the next over a one-year period. 
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METHODS 
Model Overview 
The size of the patient population with MM in the US across lines of therapy and the number 
of patient transitions from one line of therapy to the next was estimated using a 
compartmental model that represents the flow of patients with MM from disease occurrence 
to death, via two possible treatment pathways (SCT eligible; SCT non-eligible) (Figure 1). To 
account for the impact of different risk factors on disease progression,1,5-8 the model 
distinguished four groups of patients based on age at diagnosis and cytogenetic risk: older 
or younger than 65 years of age, and high or low/standard cytogenetic risk (Figure 1, as 
depicted by dotted lines). 
All newly diagnosed patients with MM enter the model as symptomatic or asymptomatic. 
Asymptomatic patients are assumed to receive no treatment until symptom occurrence. 
Symptomatic patients can transition through two treatment pathways depending on whether 
they are eligible for an SCT or not. Patients in both pathways progress from one line of 
therapy to the next as they relapse. For patients eligible for a SCT, the first line of therapy 
represents induction, SCT and maintenance therapy post SCT. In each treatment line, 
patients are allowed to die from background mortality or mortality related to their condition. 
Eventually, all patients will die since the model assumes there is no cure for MM.  
The model consists of a set of four differential equations which represent a mean 
approximation of the expected number of asymptomatic, symptomatic untreated, individuals 
who initiated on first line, and on subsequent treatment lines through time (Appendix A). The 
model parameters include estimates of MM incidence, mortality, and time to next treatment 
line (Table 1, Appendix A). The base case parameter values are shown in Table 1.  
This model includes a number of assumptions necessary for its correct interpretation: 
• Results for all lines beyond 17 are incorporated into the 17th line. 
• Patients on the SCT pathway may have up to two SCTs along their line therapy 
trajectory.   
• Asymptomatic MM (smoldering) is explicitly modeled, but no treatment is given. 
• Patterns of co-morbidities (e.g., peripheral neuropathy) are not explicit. 
• The model tracks time between starting one treatment line and starting the next. 
Treatment breaks and permanent discontinuations are not explicitly modelled. 
• There is no stratification for academic versus community care (for settings where 
these different care types exist). 
• Line of therapy is determined by disease progression, relapse, or drug toxicity 
resulting in a modification of the planned therapeutic approach.25 
• Being in the high-risk cytogenetic group does not affect SCT eligibility. 
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• Survival probabilities are characterized by an exponential function. 
• The length of each treatment line is shorter than the previous one. Minimum length of 
a treatment line is approximately one week (1/50 year). 
• Relative rate of patients transitioning from one line to another is constant across all 
lines. 
• MM-related mortality while symptomatic before first line treatment initiation is slightly 
higher (≈10%) than MM-related mortality while asymptomatic. 
• MM attributable mortality declines in the first year because of plasma cell leukemia 
patient depletion from the cohort. It is relatively constant over the subsequent years 
(≈10% increase) but then increases, especially from the 6th line of therapy and 
beyond 
• Forecasts are at the population level and not at the individual level. 
Data Sources 
To estimate the overall number of patients with MM, we used the incidence of MM obtained 
from Surveillance Epidemiology and End Results (SEER) Cancer Statistics26 applied to the 
2013 US population estimate from the US Census Bureau.27 Mortality rates were obtained 
from 2007 US National Vital Statistics.28 Other model parameters were obtained from 
targeted literature searches (Table 1). For each of these parameters, one or more 
references were identified from the literature. Internal validity of the parameter estimates 
obtained from the literature (or the degree to which the referenced studies are free from 
systematic error) is supported by the peer review process of such studies, consistency of 
results, and for some parameters, information provided from interviews with MM experts and 
market research surveys. External validity of the parameter estimates (or the degree to 
which those estimates can be applied to the overall population) is also expected, since the 
parameters’ base-case values were chosen around mid-range values and the study results 
were consistent. Some references provided data in the format required by the model, while 
others required transformation. For example, survival figures expressed as percentage of 
surviving patients at a specific time after diagnosis or treatment initiation required 
transformation into yearly rates before they could be included in the model. No ethical 
committee approval was necessary for this study. 
Sensitivity Analysis 
Parametric uncertainty analyses were conducted through probabilistic sensitivity analysis 
(PSA). The PSA was performed on key selected model parameters29 using Latin hypercube 
sampling (LHS).30 This process involved two steps: first, parameters expected to influence 
model output were selected for inclusion in the PSA, and partial rank correlation coefficients 
(PRCCs) were then computed (Appendix B, Figure B-1) to illustrate the parameters that 
were the greatest sources of heterogeneity in model output.31 Secondly, the PSA consisted 
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of varying the parameter values by sampling 1000 times from distributions specified by the 
mean value (deterministic model input) and standard errors (Appendix B, Table B2). 
Standard errors were selected to describe parameter variability observed in the data sources 
and expected in the broad population of patients with MM. Distributions were determined by 
the characteristics of the parameter and experience (e.g. beta distributions are usually 
considered for binomial data; gamma or log normal for right skew parameters; log normal for 
hazard ratios.32) 
Model Outcomes 
Model outcomes include the size of the patient population with MM potentially eligible to 
receive a MM therapy at different lines of therapy in the US, as well as the corresponding 
number of patient transitions from one line of therapy to the next over a one-year period. The 
model is designed to report outcomes at equilibrium, which is judged to have been achieved 
when the model reaches a steady state, in that the number of patients in each line no longer 
fluctuates and remains stable. All model outcomes are stratified by the eight subgroups of 
interest resulting from the combination of SCT eligibility, age group, and cytogenetic risk 
group. Model outcomes also include 95% credible intervals (analogous to a confidence 
interval with estimates obtained from the sampling results) from the PSA for both the number 
of patients and their transitions at different lines of therapy. Ninety five percent (95%) 
credible intervals were defined by the upper and lower bounds of the distribution of model 
outcomes from the PSA leaving 2.5% of the values below and above, respectively. 
RESULTS 
Prevalence of MM  
Model results are presented in Table 2. An estimated 80,219 patients were living with 
diagnosed MM in the US, of whom 70,375 patients were receiving treatment, 780 patients 
were symptomatic untreated and 9,064 patients were asymptomatic who are untreated and 
would be monitored for progression to symptomatic MM. Patient numbers stratified by SCT 
eligibility, age group, and cytogenetic risk group are shown in Table 2. Additionally, the 
model estimated that 19,330 patients with MM would die over a one-year period from 
background mortality and mortality attributable to MM.  
Patient Transitions from One Line of Therapy to the Next 
Table 3 reports the number of patient transitions from one line of therapy to the next over a 
one-year period, estimating that the total number of transitions experienced by the above 
patient population would be 96,259. A total of 18,689 patients diagnosed with MM are 
estimated to initiate first line therapy over a one-year period. Patients entering into treatment 
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line 17 and beyond were estimated at 167. Results stratified by SCT eligibility, age group, 
and cytogenetic risk group are also presented in Table 3. 
PSA results 
The results of the PSA are in Table 4, estimating 95% credible intervals (CI) for numbers of 
MM patients and the numbers of patient transitions from one line of therapy to the next. The 
results corresponding to the eight strata of interest defined by SCT eligibility, age group, and 
cytogenetic risk group are shown in Appendix C. The PSA model runtime was around three 
hours.  
DISCUSSION 
The current estimated number of patients with MM in the US is 80,219, with 70,375 on 
different lines of therapy. Over a one-year period, 19,330 deaths from all causes would be 
expected as well as 14,423 transitions from line 1 into line 2. The estimated number of 
patients initiating line 1 of therapy over one year is 18,689. Beyond line 17 of treatment, as 
anticipated, the patient prevalence was close to 0, although the number of transitions over a 
one year period could be larger as a consequence of the short time spent in those lines of 
therapy when the condition is so advanced.  
The model estimates of the patient distribution across the different lines of therapy, from the 
first to 17th line and beyond, at a snapshot in time, differed from the patient transition 
breakdown over a one-year period. For early lines of therapy, lines 1 and 2, the number of 
patient transitions over a one-year period was smaller than the number of patients at a point 
in time, as a consequence of these patients spending long periods on treatment, or without 
receiving treatment but free of disease progression and drug toxicity.25 At subsequent lines 
of therapy, the number of patient transitions decreased more slowly than the number of 
patients reflecting that the average patient spends shorter periods on successive treatment 
lines and eventually can transition through several lines of therapy over a one-year period. 
The estimated number of patients with MM in the US provided by the model, 80,219, was 
consistent with the figure estimated by SEER for 2014 of 83,367 patients. Conversely, the 
number of patients with MM who died of this disease over a one-year period was estimated 
at 11,090 (SEER data from 2014),26 while the model estimate was 16,670. This difference is 
larger than expected because one would anticipate that the number of deaths over a one-
year period is somehow lower than the number of new patients being diagnosed, as a result 
of the range of novel therapeutic alternatives providing increased patient survival over time. 
The expected small difference between incident cases and patient mortality would translate 
into a continuous steady increase of the prevalence of MM. The observed large difference in 
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the SEER data between incident cases and patient mortality would result in the prevalence 
of patients with MM increasing greatly over a short period. We hypothesize that the large 
difference between the mortality estimates of the model and those of SEER could be 
attributable to SEER reporting only mortality attributed to MM and not all mortality 
experienced by patients with MM, and also to a proportion of deaths caused by MM not 
being correctly classified as such (resulting in apparently increased background mortality 
among patients with MM).  
We have not identified any other epidemiologic models reporting on patients with MM. 
Nevertheless, there are several studies reporting on the use of epidemiologic models for 
other oncologic conditions such as prostate cancer,33,34 breast cancer,35 Hodgkin’s 
lymphoma,36,37 chronic myeloid leukemia,38 and gastrointestinal stromal tumors.24 The 
rationale for developing such models is consistent with the objectives of the model presented 
in this paper: while the epidemiology of these conditions is well documented, estimates of 
patient numbers and their distribution across subgroups of interest are scarce in the 
literature.24,33,35-37 Other research groups have developed similar models for such predictive 
purposes.34,38  
Estimates of numbers of patients in groups of interest produced by epidemiologic models 
can inform budget impact analysis and support planning of healthcare services by limiting 
the uncertainty associated with identifying patient numbers eligible for a given treatment.20,34 
This contribution can be especially relevant for conditions that have low frequency, and 
hence are difficult to study, but could qualify for orphan designation and the corresponding 
support for research and treatment development.24,39 
The model used has a complex structure and requires a large number of parameters. This is 
the consequence of modelling a complex condition whose treatment is also complex. A 
positive aspect is that the reported estimates provide a detailed picture of the patient 
population with MM. On the other hand, complexity is a limitation when it comes to finding 
supportive data for the parameters that inform the model. As a consequence, some 
parameters are supported by only one or a few sources. This limitation is common to other 
modeling studies.24 Some prognostic factors of the condition such as tumor staging or renal 
function5 were not included separately in the model. One limitation of the model to estimate 
the real difference between incident cases and patient mortality is that, by definition, in the 
model at equilibrium the number of incident patients with MM is the same as the number of 
patients dying from MM and background mortality combined. Using this dynamic model to 
look at projections for how the MM patient population will change over time would be of 
interest but it is not within the scope of this project.  
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Further research on the epidemiology of patients with MM will support more robust 
parameter estimates that can be used in this and other models. Other parameters may 
become pertinent to modeling prevalence of lines of therapy in patients with MM, which may 
warrant additional research and model development. Different stratification variables, such 
as disease stage or new risk classification, may prove important in further research. 
Additionally, future real world study results reporting on patient population and 
subpopulations at different lines of therapy and transitioning across those lines will contribute 
data to validate the model outcomes. 
In summary, the reported epidemiologic model estimates the size and the distribution of the 
patient population with MM stratified by subgroups of interest and the patients transitioning 
from one line of therapy to the next, corresponding to multiple disease relapses or treatment 
intolerances, and increasing burden as the condition progresses. This information can be 
used to assess the number of patients who could benefit from new MM therapies and their 
corresponding budgetary impact. 
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TABLES 
Table 1. Model Base Case Parameter Values for the US  
Parameter  Base Case Units Reference 
Population  
   
Population size 316,128,839 persons 27 
Background death rate of adults 40-64 years 0.008 proportion per 
year 
28 
Background death rate of adults ≥65 years 0.060 proportion per 
year 
28 
MM epidemiology 
   
Incidence of MM 0.000061 proportion per 
year 
5,26 
Proportion patients <65 years at MM 
diagnosis 
38.00% % 5,26 
Proportion in high cytogenetic risk group at 
MM diagnosis 
35.00% % 5,6,9,40-46 
Proportion symptomatic at MM diagnosis 87.50% % 47-50 
Median duration for progression from 
asymptomatic (smoldering) MM to 
symptomatic MM 
58 months 47,48,50 
MM-related death rate while asymptomatic 
(smoldering), <65 years, MM patients 
0.0040 proportion per 
year 
42,50
 
MM-related death rate while asymptomatic 
(smoldering), ≥65 years, MM patients 
0.0400 proportion per 
year 
42,50
 
MM-related death rate while symptomatic 
MM before treatment initiation, <65 years 
0.0045 proportion per 
year 
assumption 
MM-related death rate while symptomatic 
MM before treatment initiation, ≥65 years 
0.0450 proportion per 
year 
assumption 
Treatment initiation 
   
Time from diagnosis of symptomatic MM to 
treatment initiation 
0.500 months 42,45 
Proportion <65 years initiating SCT pathway 30.00% % 51,52 
Proportion ≥65 years initiating SCT pathway 10.00% % 51,52 
MM-related death rates on treatment 
pathway 
 
  
Patients <65 years, standard/low cytogenetic 
risk, non-SCT treatment pathway: treatment 
line 1 
0.10 Proportion per 
year 
11,53
 
MM-related death rate ratio: SCT compared 
to non-SCT 
0.70 None (ratio) 9,54 
MM-related death rate ratio: ≥65 year age 
group compared to <65 year age group 
1.50 None (ratio) 9,49,52,55,56 
MM-related death rate ratio: high cytogenetic 
risk group compared to standard/low 
cytogenetic risk group 
2.25 None (ratio) 6,40,41,46,54,57-59 
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Parameter  Base Case Units Reference 
MM-related death rate ratio: 2nd line 
compared to 1st line treatment 
1.00 None (ratio) 1,15,60 
MM-related death rate ratio: 3rd line 
compared to 2nd line treatment 
1.10 None (ratio) 1,15,60 
MM-related death rate ratio: 4th line 
compared to 3rd line treatment 
1.15 None (ratio) 1,15,60 
MM-related death rate ratio: 5th line 
compared to 4th line treatment 
1.20 None (ratio) 1,15,60 
MM-related death rate ratio: 6th line 
compared to 5th line treatment 
1.25 None (ratio) 1,15,60 
MM-related death rate ratio: 7th line 
compared to 6th line treatment 
1.40 None (ratio) 1,15,60 
MM-related death rate ratio: 8th line 
compared to 7th line treatment (applicable to 
subsequent lines, up to 17, compared to the 
previous line) 
1.50 None (ratio) 1,15,60 
Time to next line of treatment 
   
Treatment duration on treatment line 1*  
(patients <65 years, standard/low 
cytogenetic risk, SCT pathway) 
35.0 Months 5,40,42,46,49,58,59,61,62 
Time to next line of treatment: n+1th line 
compared to nth line treatment 
0.80 None (ratio) 41 
Time to next line of treatment: ≥65 year age 
group compared to <65 year age group 
0.75 None (ratio) 63,64 
Time to next line of treatment: high 
cytogenetic risk group compared to 
standard/low cytogenetic risk group 
0.45 None (ratio) 6,40,41,43,46,57,58 
Treatment duration on treatment line 1* 
(patients <65 years, standard/low 
cytogenetic risk, non-SCT pathway) 
27.0 Months 42,43,49,65,66 
* Defined as time between initiating treatment line 1 and initiating treatment line 2. 
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Table 2. Estimated Total Number of Prevalent MM Cases in the US by Line of Therapy 
and Patient Subgroups of Interest  
Treatment 
Line Total SCT Eligibility SCT Non Eligibility 
  Low/Standard 
Cytogenetic 
Risk 
High 
Cytogenetic 
Risk 
Low/Standard 
Cytogenetic Risk 
High 
Cytogenetic 
Risk 
  
<65 yrs 
≥65 
yrs 
<65 
yrs ≥65 yrs <65 yrs ≥65 yrs 
<65 
yrs 
≥65 
yrs 
Line 1 23,629 3,375 1,196 825 306 6,000 8,351 1,465 2,111 
Line 2 15,350 2,287 742 562 198 4,017 5,201 985 1,358 
Line 3 10,249 1,584 477 390 132 2,746 3,346 676 898 
Line 4 6,966 1,114 314 274 89 1,901 2,201 469 604 
Line 5 4,786 790 210 193 61 1,325 1,469 328 410 
Line 6 3,301 561 142 136 42 925 987 229 279 
Line 7 2,252 394 95 95 28 637 657 158 188 
Line 8 1,501 271 62 65 19 428 427 106 123 
Line 9 971 181 40 43 12 279 269 69 78 
Line 10 605 116 25 27 7 175 164 43 48 
Line 11 363 72 15 17 4 106 95 26 28 
Line 12 206 43 8 10 2 61 52 15 15 
Line 13 111 24 5 5 1 33 27 8 8 
Line 14 54 12 2 3 0 17 13 4 3 
Line 15 23 6 1 1 0 8 5 1 1 
Line 16 7 2 0 0 0 3 2 0 0 
Line 17 
and 
greater 
2 1 0 0 0 1 0 0 0 
Total 
patients 
on 
treatment  
70,375 10,833 3,333 2,646 901 18,662 23,266 4,582 6,152 
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Table 3. Number of MM Patient Transitions in the US by Line of Therapy and Patient 
Subgroups of Interest  
New Treatment 
SCT Eligibility SCT Non Eligibility 
Low/standard 
cytogenetic 
risk 
High 
cytogenetic 
risk 
Low/standard 
cytogenetic risk 
High 
cytogenetic risk 
Regimens 
Total <65 
yrs 
≥65 
yrs 
<65 
yrs 
≥65 
yrs 
<65 
yrs 
≥65 
yrs 
<65 
yrs 
≥65 
yrs 
Line 1 18,689 1,418 742 763 399 3,309 6,680 1,781 3,597 
Line 2 14,423 1,155 545 627 309 2,661 4,928 1,440 2,758 
Line 3 11,677 979 422 533 250 2,227 3,837 1,210 2,219 
Line 4 9,715 848 339 463 208 1,902 3,085 1,038 1,832 
Line 5 8,225 746 278 406 176 1,646 2,535 900 1,538 
Line 6 7,038 662 233 358 150 1,433 2,113 786 1,303 
Line 7 6,047 589 196 316 129 1,250 1,773 686 1,108 
Line 8 5,131 518 164 275 109 1,075 1,472 590 928 
Line 9 4,241 444 134 234 90 900 1,192 493 754 
Line 10 3,396 370 107 193 72 730 934 399 591 
Line 11 2,616 298 82 153 55 571 704 310 443 
Line 12 1,920 230 60 116 40 427 505 229 313 
Line 13 1,334 169 42 84 28 303 342 160 206 
Line 14 862 117 28 57 17 202 215 103 123 
Line 15 511 76 17 35 10 125 124 60 64 
Line 16 267 45 9 19 5 70 63 30 26 
Line 17 
and greater 
167 40 5 12 1 52 37 14 6 
Total 
transitions 
96,259 8,704 3,403 4,644 2,048 18,883 30,539 10,229 17,809 
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Table 4. Median and Credible Intervals of the Number of MM Patients and Number of 
Patient Transitions by Line of Therapy in the US 
Treatment Lines 
Number of MM Patients 
Number of Patient Therapy Line 
Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 23,584 22,236 25,029 18,696 18,558 18,817 
Line 2 15,346 13,845 16,760 14,415 13,489 15,176 
Line 3 10,234 8,908 11,515 11,658 10,348 12,811 
Line 4 6,955 5,847 8,053 9,699 8,223 11,085 
Line 5 4,778 3,893 5,685 8,214 6,670 9,744 
Line 6 3,298 2,609 4,038 7,028 5,483 8,630 
Line 7 2,252 1,723 2,850 6,042 4,531 7,669 
Line 8 1,502 1,106 1,975 5,131 3,695 6,766 
Line 9 975 687 1,338 4,244 2,919 5,872 
Line 10 612 409 886 3,403 2,223 4,964 
Line 11 369 232 568 2,629 1,612 4,075 
Line 12 213 125 353 1,937 1,107 3,273 
Line 13 116 63 210 1,350 714 2,487 
Line 14 59 30 119 878 428 1,788 
Line 15 28 13 63 525 236 1,212 
Line 16 12 5 32 279 120 719 
Line 17 and 
greater 
9 5 22 192 77 523 
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Figure 1. Model to Assess Prevalence of Patients with MM at Different Treatment Lines 
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Appendix A: Model Parameters and Equations 
Table A - 1. Model Parameters 
 Description 

	
 
Incidence of MM (all stages) for demographic group  (proportion/year) 
 Proportion of MM patients that is symptomatic at diagnosis* 
 Progression rate of asymptomatic MM to symptomatic* 
 Progression rate of symptomatic MM to treatment* (per year) 

	
 
Background death rate for demographic group†  (per year) 
	
	
 
MM-related death rate for demographic group  as yet untreated, asymptomatic (per 
year) 


	
 
MM-related death rate for demographic group  as yet untreated, symptomatic MM (per 
year) 

	
 
Proportion symptomatic initiating first line of  treatment within demographic group  
who are assigned to each treatment pathway¹  
 MM-related death rate for demographic group  on treatment pathway  and line of 
therapy  (per year) 
/
	
 
Time to next line of treatment for patients in demographic group  on treatment pathway 
 and line of therapy  (years) 
MM = multiple myeloma 
*Assumption that this parameter has the same value regardless of risk and age group. 
†Demographic groups= <65 years and low/standard cytogenetic group; ≥65 years and low/standard cytogenetic group; <65 
years and high cytogenetic group; ≥65 years and high cytogenetic group; 
¹Treatment pathways= at least one SCT is performed; no SCT is performed 
 
Model Equations 
The model initiates upon diagnosis with MM.  Individuals flow between states in the model. 
Patients may be diagnosed with asymptomatic 	() or symptomatic () MM, where u is 
demographic group (currently four groups according to age group and cytogenetic risk 
group).  Asymptomatics () receive new cases with proportion ( − ) of the total 
incidence 
	
.  Individuals become symptomatic at rate	.  Symptomatics () receive a 
proportion  of the incident cases directly and initiate treatment at a rate  with proportions 

	
 in each of the two treatment pathways. Asymptomatics experience MM-related 
mortality at rate		
	
whilst symptomatics experience MM-related mortality at rate 

	
. 
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Each treatment state is represented by , where  is demographic group,   is 
treatment pathway (currently: 1 = at least one SCT is performed; 2 = no SCT is performed), 
and  is line of therapy).Treated cases progress through 17 lines of treatment (index  from 
1 to 17) at rate 	  and experience MM-related mortality at rate . Asymptomatic, 
symptomatic, and treated individuals are all subject to background death rate	 . 
Line of therapy is understood as one or more cycles of a planned treatment program (single 
agent, combination therapy, or sequence of treatments administered as planned).  A new 
line of therapy is assumed to start when a planned treatment program is modified to include 
other drugs as a result of disease progression, relapse or toxicity, or when a planned period 
off-treatment is interrupted because additional treatment for MM is required.25 
For patients undergoing SCTs, first-line treatment usually represents the package of 
treatments that are required for an SCT procedure (i.e., includes induction therapy as well as 
SCT). A second SCT is recorded as second-line treatment. In some cases, a first SCT could 
also take place at a line of therapy greater than line 1. 
Asymptomatic MM: 


= 
	 	 −  −  + 
	 + 	
	  
Where  = 1...4 
Symptomatic MM, untreated: 


= 
	  + − 	 + 
	 + 

	  
Where  =1...4 
MM treatment stages 
First-line treatment: 


= 
	 − 
	 +  + 
	  
Where  = 1...4;  = 1, 2;  = 1 
Subsequent treatment lines ( > 1): 
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

= 
	 − 
	 +  + 
	  
Where  = 1...4;  = 1,2;  = 2…20 
The values of MM-related death rates and MM time to next treatment (TTNT) durations for 
each MM treatment state are related to a baseline MM-related death rate and two baseline 
time to next line of treatment values: 
• The baseline MM-related death rate is for MM patients on the first line of treatment, 
on the non-SCT pathway, < 65 years of age and in the low/standard cytogenetic risk 
group. 
• MM-related death rates for all other treated MM health states are derived from the 
baseline rate using the following death rate relative risks (RR): 
- RR for patients ≥ 65 years compared to < 65 years 
- RR for patients in the high cytogenetic risk group compared to the 
low/standard-risk group 
- RR for patients on the SCT pathway compared to those on the non-SCT 
pathway 
- RR for patients on the n+1th line of treatment compared to those on the nth 
line of treatment 
• The baseline TTNT values are for MM patients on the first line of treatment, < 65 
years of age and in the low cytogenetic risk group. There is one baseline value for 
patients on the SCT treatment pathway and another value for patients on the non-
SCT pathway. 
• TTNT values for all other treated MM health states are derived from the baseline 
values using the following TTNT RRs: 
- RR for patients ≥ 65 years compared to < 65 years 
- RR for patients in the high cytogenetic risk group compared to the 
low/standard-risk group 
- RR for patients on the n+1th line of treatment compared to those on the nth 
line of treatment 
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Appendix B: Probabilistic Sensitivity Analysis 
Based on model influence diagram face validity discussions, the parameters expected to 
influence model output selected for inclusion in the PSA were: 
Population inputs:  
1. Proportion patients < 65 years at MM diagnosis (prop_young in Figure B-1 below) 
2. Proportion in low/standard cytogenetic risk group at MM diagnosis (prop_lowrisk) 
3. Proportion symptomatic at MM diagnosis (prop_sympt) 
Treatment inputs: 
4. Proportion < 65 years initiating SCT pathway (prop_less65_SCT) 
5. Baseline MM-related death rate; patients < 65 years, low/standard cytogenetic risk, 
non-SCT treatment pathway: treatment line 1 (baseline MM death rate) 
6. MM-related death rate ratio: ≥ 65 year age group compared to < 65 year age group 
(RR_mort_oldage) 
7. MM-related death rate ratio: high cytogenetic risk group compared to low/standard 
cytogenetic risk group (RR_mort_highrisk) 
We used the LHS method30. Running the model with model parameters for the baseline 
country produced the PRCCs shown in Figure B-1. The magnitude of each PRCC quantifies 
the importance of each parameter, with the sign of the PRCC value indicating the specific 
qualitative relationship between the input and the output variable: positive values of PRCC 
imply that increasing the value of the input variable will lead to an increase in the output 
variable (number of forecasted patients with MM). As a general rule, parameters with the 
largest influence are defined as those with a PRCC greater than 0.4 or less than −0.4. 
Figure B-1 shows that the parameters with the greatest influence on the model outcomes for 
the baseline country are all the MM-related death rates ratios [5-7 from list above], with the 
relationship being negative. Additionally, the proportion of patients in low cytogenetic risk 
group [2] and the proportion symptomatic [3] are shown to have a great positive influence on 
model outcomes. The observed low PRCCs for the proportion of young patients [1] and the 
proportion of young patients initiating SCT [4] imply that their influence on the model 
outcomes is expected to be low.   
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Figure B-2. Partial Rank Correlation Coefficients for Key Model Parameters 
 
 
 
Table B - 2. Probabilistic Sensitivity Analysis Parameters 
Parameter (unit) Base Case 
Standard 
Error Distribution 
Proportion patients <65 years at MM diagnosis 38.00% 1.80% Beta 
Proportion in high cytogenetic risk group at 
MM diagnosis 
35.00% 2.50% Beta 
Proportion symptomatic at MM diagnosis 87.50% 1.50% Beta 
Proportion <65 years initiating SCT pathway 85.00% 2.5% Beta 
Proportion patients <65 years, standard/low 
cytogenetic risk, non-SCT treatment pathway: 
treatment line 1 
0.100 0.010 Gamma 
MM-related death rate ratio: ≥65 year age 
group compared to <65 year age group 
1.50 0.15 Lognormal 
MM-related death rate ratio: high cytogenetic 
risk group compared to standard/low 
cytogenetic risk group 
2.25 0.25 Lognormal 
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Appendix C: PSA Results for Subgroups of Interest 
Table C - 1. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients <65 Years, Low/Moderate 
Cytogenetic Risk and Eligible for SCT. 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 3,357 2,792 4,030 1,414 1,177 1,693 
Line 2 2,270 1,882 2,773 1,150 956 1,380 
Line 3 1,570 1,284 1,929 972 806 1,187 
Line 4 1,099 887 1,363 840 687 1,032 
Line 5 774 618 976 734 593 911 
Line 6 548 431 702 646 515 814 
Line 7 384 297 503 570 449 732 
Line 8 263 200 351 499 386 653 
Line 9 175 129 240 425 324 568 
Line 10 113 81 159 353 261 485 
Line 11 70 49 102 283 204 398 
Line 12 42 28 64 218 151 320 
Line 13 24 15 39 160 107 247 
Line 14 13 8 22 111 70 182 
Line 15 7 4 12 72 43 128 
Line 16 3 2 6 43 24 83 
Line 17 and 
greater 
5 4 7 43 21 95 
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Table C - 2. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients ≥65 Years, Low/Moderate 
Cytogenetic Risk and Eligible for SCT 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 1,195 1,080 1,316 744 682 798 
Line 2 740 643 846 545 492 600 
Line 3 475 396 561 421 366 482 
Line 4 314 248 383 338 282 400 
Line 5 210 159 265 279 221 341 
Line 6 142 102 186 233 176 294 
Line 7 95 65 129 197 141 257 
Line 8 63 40 90 165 112 223 
Line 9 41 24 61 135 86 193 
Line 10 25 14 41 108 63 163 
Line 11 15 8 27 83 45 135 
Line 12 9 4 17 62 30 108 
Line 13 5 2 10 43 19 83 
Line 14 3 1 6 29 11 61 
Line 15 2 1 4 17 6 42 
Line 16 1 1 2 10 3 26 
Line 17 and 
greater 
4 4 4 4 3 11 
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Table C - 3. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients <65 Years, High 
Cytogenetic Risk and Eligible for SCT 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 822 631 1,033 759 608 940 
Line 2 561 409 723 624 479 785 
Line 3 388 265 528 532 389 687 
Line 4 271 175 386 461 314 627 
Line 5 192 116 282 402 260 572 
Line 6 136 76 208 355 214 522 
Line 7 95 49 153 315 176 480 
Line 8 66 30 111 274 141 440 
Line 9 44 18 79 235 108 398 
Line 10 28 11 56 194 80 352 
Line 11 18 6 38 154 57 306 
Line 12 11 3 25 117 38 258 
Line 13 6 2 17 85 23 209 
Line 14 3 1 11 58 13 165 
Line 15 2 1 6 37 7 123 
Line 16 1 1 4 21 3 85 
Line 17 and 
greater 
4 4 5 8 3 42 
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Table C - 4. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients ≥65 Years, High 
Cytogenetic Risk and Eligible for SCT 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 305 252 362 400 344 457 
Line 2 199 148 247 308 254 366 
Line 3 133 89 174 251 186 312 
Line 4 90 55 124 209 140 274 
Line 5 62 34 90 177 108 243 
Line 6 43 22 66 151 84 220 
Line 7 29 14 47 130 67 200 
Line 8 20 8 34 110 51 179 
Line 9 13 5 24 91 37 160 
Line 10 8 3 17 73 26 140 
Line 11 5 2 12 56 17 119 
Line 12 3 1 8 41 10 98 
Line 13 2 1 5 28 6 78 
Line 14 1 1 3 18 3 59 
Line 15 1 1 2 10 2 41 
Line 16 1 1 2 5 1 26 
Line 17 and 
greater 
2 2 2 3 2 16 
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Table C - 5. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients <65 Years, Low/Moderate 
Cytogenetic Risk and Not Eligible for SCT 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 6,011 5,350 6,686 3,309 2,967 3,675 
Line 2 4,024 3,519 4,526 2,667 2,373 2,966 
Line 3 2,757 2,373 3,136 2,232 1,951 2,510 
Line 4 1,906 1,614 2,211 1,911 1,644 2,173 
Line 5 1,330 1,106 1,567 1,651 1,398 1,915 
Line 6 929 760 1,118 1,439 1,196 1,696 
Line 7 641 512 792 1,256 1,027 1,512 
Line 8 430 335 549 1,081 864 1,336 
Line 9 281 211 371 905 704 1,154 
Line 10 176 129 242 735 553 971 
Line 11 107 74 154 574 418 789 
Line 12 62 41 93 431 299 622 
Line 13 34 21 55 307 204 464 
Line 14 18 10 30 205 128 331 
Line 15 9 5 16 128 75 221 
Line 16 4 2 8 72 39 137 
Line 17 and 
greater 
5 4 8 61 29 133 
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Table C - 6. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients ≥65 Years, Low/Moderate 
Cytogenetic Risk and Not Eligible for SCT 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 8,341 7,522 9,219 6,689 6,133 7,180 
Line 2 5,182 4,464 5,969 4,919 4,435 5,436 
Line 3 3,338 2,723 4,001 3,820 3,290 4,400 
Line 4 2,202 1,702 2,735 3,074 2,508 3,684 
Line 5 1,472 1,078 1,897 2,533 1,958 3,146 
Line 6 989 687 1,324 2,114 1,549 2,726 
Line 7 660 430 924 1,773 1,231 2,375 
Line 8 432 259 636 1,475 962 2,065 
Line 9 273 152 429 1,199 720 1,766 
Line 10 167 84 282 941 522 1,478 
Line 11 97 44 180 709 358 1,201 
Line 12 54 22 111 508 229 940 
Line 13 29 10 65 344 136 703 
Line 14 14 4 37 216 74 495 
Line 15 7 2 19 122 36 323 
Line 16 3 1 9 61 15 188 
Line 17 and 
greater 
3 3 7 33 7 130 
 
  
Page 33 of 50
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
33 
 
Table C - 7. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients <65 Years, High 
Cytogenetic Risk and Not Eligible for SCT 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 1,460 1,194 1,733 1,779 1,514 2,059 
Line 2 979 747 1,220 1,436 1,174 1,705 
Line 3 674 476 877 1,203 919 1,500 
Line 4 470 305 641 1,035 731 1,347 
Line 5 329 201 467 902 586 1,230 
Line 6 230 131 345 788 482 1,118 
Line 7 159 82 252 688 391 1,030 
Line 8 107 49 183 591 305 938 
Line 9 70 29 130 496 228 845 
Line 10 45 16 91 402 162 748 
Line 11 27 8 62 314 108 644 
Line 12 16 4 41 232 67 540 
Line 13 9 2 26 163 39 430 
Line 14 5 1 16 107 20 330 
Line 15 2 1 10 64 9 238 
Line 16 1 1 6 34 4 153 
Line 17 and 
greater 
3 3 6 6 2 43 
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Table C - 8. Median and Credible Intervals of the Number of Patients and Number of 
Patient Transitions, by Line of Therapy: Patients ≥65 Years, High 
Cytogenetic Risk and Not Eligible for SCT 
Treatment Lines 
Number of Patients Number of Patient Transitions 
 95% Credible Interval  95% Credible Interval 
Median Lower Upper Median Lower Upper 
Line 1 2,106 1,718 2,512 3,597 3,090 4,111 
Line 2 1,360 989 1,709 2,747 2,241 3,277 
Line 3 902 580 1,205 2,217 1,612 2,787 
Line 4 606 355 857 1,836 1,181 2,454 
Line 5 413 219 619 1,540 903 2,177 
Line 6 281 136 448 1,308 693 1,963 
Line 7 189 82 324 1,109 537 1,770 
Line 8 125 47 231 926 401 1,590 
Line 9 80 26 163 754 284 1,397 
Line 10 49 13 111 591 189 1,210 
Line 11 29 7 75 442 117 1,005 
Line 12 16 3 50 312 67 814 
Line 13 9 2 32 204 34 629 
Line 14 4 1 20 119 15 452 
Line 15 2 1 12 60 6 292 
Line 16 1 1 6 22 2 152 
Line 17 and 
greater 
1 1 2 4 1 39 
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Diagnosis, 
symptomatic 
1
st
 line 
No SCT  
SCT  
2
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 line 3
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 line 
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progression to 
symptomatic 
Background mortality and MM-related mortality (μ
i
+ν
ijk
) 
2
nd
 line 3
rd
 line ………… ≥20
th
 line 1
st
 line 
Background mortality and MM-related mortality (μ
i
+ν
ijk
) 
Dotted lines behind each blue compartment denote strata  
(by age (<65, 65+ years) and high or low/standard cytogenetic risk group) 
i.e. 4 compartments for each 1 shown here 
incidence 
Diagnosis, 
asymptomatic 
(smoldering) 
μi+νijk – background and MM-related mortality. Subscripts denote differences in 
mortality rates by treatment state. e.g., mortality varies by SCT eligibility to reflect the 
higher frailty of SCT ineligible patients.  
SCT (stem cell transplant): Induction therapy pre-SCT and maintenance post-SCT is modeled as one line of 
therapy for the SCT treatment pathway.  
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